Aevitas Therapeutics

4 articles about Aevitas Therapeutics

• Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H

  4/24/2023

  Aevitas Therapeutics, Inc. today announced the execution of an asset purchase agreement for 4DMT to acquire Aevitas’ proprietary rights to its short-form human complement factor H (“sCFH”) asset for the treatment of complement-mediated diseases.

• 

  BioSpace Movers & Shakers, Feb. 26

  2/26/2021

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Aevitas Therapeutics Appoints Markus Peters, Ph.D., M.Sc., as Chief Executive Officer

  2/22/2021

  Aevitas Therapeutics, Inc. (“Aevitas”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company focused on the development of novel gene therapy approaches for complement-mediated diseases, today announced the appointment of Markus Peters, Ph.D., M.Sc., as President and Chief Executive Officer.

• Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, To Develop Novel AAV Gene Therapy Treatments For Complement-Mediated Diseases

  8/14/2017